It’s “Mission accomplished” for avocado distributor’s IPO
Mission Produce is going on the offensive in the booming global avocado market, with $75 million in new capital from its Oct. 1 initial public offering. The Oxnard-based global avocado packer and distributor went public at $12 per share, a step down from its initial target of $15-$17 per share. The deal netted $75 million Read More →
Dubroff: Mission Produce IPO holds lessons for industry, region
UPDATE: Mission Produce began trading on the Nasdaq at 12:16 p.m. on Oct. 1. Follow the stock here. The window for initial public stock offerings rarely opens as wide as it has in the fall of 2020. That’s remarkable given the COVID-19 pandemic, the election campaign and governments racking up debt like crazy. But after Read More →
Arcutis shares up on news of public, private offerings
Arcutis Biotherapeutics saw a 15 percent rise in its share price after it said Sept. 29 that it will offer 4 million shares to the public and sell another $35 million in stock to an affiliate of one of its directors. Arcutis closed at $31.04, a gain of $4.28 after it announced the dual track Read More →
Cure closes $20M CBD acquisition
Cure Pharmaceutical, an Oxnard cannabis products manufacturer, has completed its $20 million cash-and-stock buyout of the CBD company Sera Labs, a deal Cure says will help it reach positive cash flow in around 18 months. Cure’s stock, which is traded on the over-the-counter markets, fell 3 percent following the announcement, closing at $1.29 per share Read More →
Mission Produce could join three-comma club with $1B-plus IPO
Mission Produce put a $1.18 billion price tag on its avocado operation, announcing in a Sept. 23 Securities and Exchange Commission filing that it plans to raise around $106 million in its initial public offering. The Oxnard-based avocado distributor said it plans to offer some 6.25 million shares of common stock for $15-$17 per share. Read More →
Amgen to team with Eli Lilly on COVID treatment
Thousand Oaks biotech giant Amgen announced another strategy to help address the coronavirus pandemic, entering into a manufacturing agreement with Eli Lilly to produce COVID-19 antibodies. Eli Lilly, based in Indianapolis, has been pursuing several antibody treatments for the virus, the two companies said in a Sept. 17 news release. With access to Amgen’s manufacturing Read More →
Mission Produce plants seed for IPO
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
